Organogenesis Holdings Inc. ORGO Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Organogenesis Holdings Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Organogenesis Holdings Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Organogenesis Holdings Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Organogenesis Holdings Inc.'s additional paid-in capital?
- Organogenesis Holdings Inc. (ORGO) reported additional paid-in capital of $300.78M in Q1 2026.
- How has Organogenesis Holdings Inc.'s additional paid-in capital changed year-over-year?
- Organogenesis Holdings Inc.'s additional paid-in capital decreased by 0.4% year-over-year, from $301.84M to $300.78M.
- What is the long-term trend for Organogenesis Holdings Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Organogenesis Holdings Inc.'s additional paid-in capital has grown at a 0.4% compound annual growth rate (CAGR), from $296.83M to $303.19M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.